TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6096982

Group type: EXPERIMENTAL
Intervention: Continuous subcuticular absorbable (Dexon) suture
Number of subjects: 113

Group type: COMPARATOR
Intervention: Metal skin staples (Autosuture)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Nylon vertical mattress suture
Number of subjects: 113

Group type: COMPARATOR
Intervention: Adhesive sutureless skin closure (Op‐site)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Overall incidence of wound infection
Number of subjects: 113
Study: 31331572

Group type: EXPERIMENTAL
Intervention: Achillea wilhelmsii capsules, twice daily for 4 weeks
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo, twice daily for 4 weeks
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Achillea wilhelmsii capsules
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 28434633

Group type: EXPERIMENTAL
Intervention: Testosterone propionate 1% ointment twice a day for 30 days
Number of subjects: 35
Study: 25883103

Group type: EXPERIMENTAL
Intervention: Montelukast (group M, n = 30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (group C, n = 30)
Number of subjects: 60
Study: 24922664

Group type: EXPERIMENTAL
Intervention: IGF1R mRNA positive tumors
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: IGF1R protein expression
Number of subjects: 33
Study: 22932399

Group type: EXPERIMENTAL
Intervention: Protein C
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 20634190

Group type: EXPERIMENTAL
Intervention: IVIG 500 mg/kg
Number of subjects: 82

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 82
Study: 17198918

Group type: EXPERIMENTAL
Intervention: Indapamide SR 1.5 mg
Number of subjects: 187

Group type: COMPARATOR
Intervention: Enalapril 10 mg
Number of subjects: 187
Study: 16651204

Group type: EXPERIMENTAL
Intervention: Testim 1% (5 g)
Number of subjects: 151

Group type: COMPARATOR
Intervention: AndroGel 1% (5 g)
Number of subjects: 151
Study: 12809386

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral men's group
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Couple's group
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Safety and stabilization group
Number of subjects: 268

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 268
Study: 9440386

Group type: EXPERIMENTAL
Intervention: Oligopeptide-based complete formula (OPD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Whole-protein-based complete formula (WPD)
Number of subjects: 0
Study: 8541168

Group type: EXPERIMENTAL
Intervention: Encainide or flecainide treatment
Number of subjects: 260

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 260
Study: 2235229

Group type: EXPERIMENTAL
Intervention: Group classes discussing myths, problems, and benefits of breast-feeding
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Individual prenatal counseling with a pediatrician or nurse practitioner
Number of subjects: 159

Group type: COMPARATOR
Intervention: Control group with no additional prenatal education
Number of subjects: 159

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Group classes
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Individual sessions
Number of subjects: 159
Study: 637281

Group type: EXPERIMENTAL
Intervention: bupivacaine 0.75%
Number of subjects: 147

Group type: COMPARATOR
Intervention: bupivacaine 0.5%
Number of subjects: 147

Group type: COMPARATOR
Intervention: mepivacaine 1.5% with adrenaline
Number of subjects: 147
Study: 31101184

Group type: EXPERIMENTAL
Intervention: Rituximab (375 mg/m2)
Number of subjects: 0
Study: 28175316

Group type: EXPERIMENTAL
Intervention: Algorithm including AMH, AFC, age and BMI
Number of subjects: 308

Group type: COMPARATOR
Intervention: Algorithm including only AFC, age and BMI (Control)
Number of subjects: 308
Study: 25533774

Group type: EXPERIMENTAL
Intervention: Losartan (100 mg per day)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 133
Study: 23164311

Group type: EXPERIMENTAL
Intervention: Early developmental intervention (EDI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no early developmental intervention)
Number of subjects: 0
Study: 21327351

Group type: EXPERIMENTAL
Intervention: Spatial‐numerical training program using full‐body spatial movement on a digital dance mat
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non‐spatial control training
Number of subjects: 0
Study: 19308816

Group type: EXPERIMENTAL
Intervention: High peak reaction force of 123 N (peak torque=8 Nm, build-up time=250 ms)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Low peak reaction force of 5 N (peak torque=2 Nm, build-up time=50 ms)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 24
Study: 17053058

Group type: EXPERIMENTAL
Intervention: Low-power laser therapy (LPLT)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (no LPLT)
Number of subjects: 38
Study: 16170158

Group type: EXPERIMENTAL
Intervention: Dexamethasone (DEXA) 8 mg/m2 during induction and DEXA 6 mg/m2 during the intensifications
Number of subjects: 359

Group type: COMPARATOR
Intervention: Prednisolone (PRED) 60 mg/m2 during induction and PRED 40 mg/m2 during four intensifications in the SR group and three intensifications in the IR group
Number of subjects: 359
Study: 11991446

Group type: EXPERIMENTAL
Intervention: Alendronate 80 mg
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Alendronate 160 mg
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Alendronate (both dosages)
Number of subjects: 81
Study: 9473831

Group type: EXPERIMENTAL
Intervention: Dexamethasone 10 mg preoperative dose
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no dexamethasone)
Number of subjects: 20
Study: 7630676

Group type: EXPERIMENTAL
Intervention: Sorbitol
Number of subjects: 116

Group type: COMPARATOR
Intervention: Magnesium citrate
Number of subjects: 116

Group type: COMPARATOR
Intervention: Magnesium sulfate
Number of subjects: 116

Group type: COMPARATOR
Intervention: Water
Number of subjects: 116
Study: 2550634

Group type: EXPERIMENTAL
Intervention: Lisinopril 20 mg once daily
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 354746

Group type: EXPERIMENTAL
Intervention: Co-trimoxazole (single dose, intravenous infusion)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 95
Study: 31183442

Group type: EXPERIMENTAL
Intervention: Enhanced recovery after surgery (ERAS)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 220
Study: 29273261

Group type: EXPERIMENTAL
Intervention: Weekly irinotecan at 95 mg/m2 for ∗1∗1 genotype
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Weekly irinotecan at 80 mg/m2 for ∗1∗28 genotype
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Weekly irinotecan at 80 mg/m2 for ∗1∗1 genotype
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Weekly irinotecan at 65 mg/m2 for ∗1∗28 genotype
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Weekly irinotecan at 80 mg/m2 and 65 mg/m2
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Capecitabine at 625 mg/m2
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiation therapy (IMRT)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Grade 3 to 4 toxicities
Number of subjects: 26
Study: 26630417

Group type: EXPERIMENTAL
Intervention: Percutaneous vertebroplasty (PVP)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Conservative treatment (CV)
Number of subjects: 135
Study: 24644195

Group type: EXPERIMENTAL
Intervention: Psychoeducational interventions (one-to-one and group format)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Psychoeducational interventions
Number of subjects: 0
Study: 22554171

Group type: EXPERIMENTAL
Intervention: LNG-IUS(12)
Number of subjects: 742

Group type: EXPERIMENTAL
Intervention: LNG-IUS(16)
Number of subjects: 742

Group type: COMPARATOR
Intervention: LNG-IUS(20)
Number of subjects: 742
Study: 20427496

Group type: EXPERIMENTAL
Intervention: NNC126‐0083
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 18062345

Group type: EXPERIMENTAL
Intervention: TAMMEF (Therapeutic Application of a Musically Modulated Electromagnetic Field)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: ELF (Extremely Low Frequencies electromagnetic fields)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Simulated field
Number of subjects: 60
Study: 15596958

Group type: EXPERIMENTAL
Intervention: Tilt-table tests
Number of subjects: 0
Study: 11962228

Group type: EXPERIMENTAL
Intervention: Peer-led nutrition education intervention
Number of subjects: 1000
Study: 10528662

Group type: EXPERIMENTAL
Intervention: Bicarbonate dialysate
Number of subjects: 26

Group type: COMPARATOR
Intervention: Lactate dialysate
Number of subjects: 26
Study: 7738459

Group type: EXPERIMENTAL
Intervention: Active arm enrollment for desperate volunteers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Randomized control for less desperate patients
Number of subjects: 0
Study: 1702012

Group type: EXPERIMENTAL
Intervention: Ondansetron (8 mg tds orally)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Metoclopramide (10 mg tds orally)
Number of subjects: 82
Study: 347876

Group type: EXPERIMENTAL
Intervention: Bromperidol (14-23 mg/day during acute treatment, average maintenance dose approximately 8 mg, total doses from 3-39 mg for up to four months)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Bromperidol (acute treatment)
Number of subjects: 30
Study: 31713282

Group type: EXPERIMENTAL
Intervention: Bread or rusks
Number of subjects: 1728

Group type: EXPERIMENTAL
Intervention: Chocolate milk
Number of subjects: 1728

Group type: COMPARATOR
Intervention: Frequency of breakfast consumption
Number of subjects: 1728
Study: 31162597

Group type: EXPERIMENTAL
Intervention: Whole-grain pasta enriched with barley β-glucans and Bacillus coagulans BC30, 6086 (INN)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Whole-grain control pasta (CTR)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Whole-grain pasta enriched with barley β-glucans and Bacillus coagulans BC30, 6086 (INN) in obese subgroup
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Whole-grain pasta enriched with barley β-glucans and Bacillus coagulans BC30, 6086 (INN) in hyperglycemic subgroup
Number of subjects: 41
Study: 28454796

Group type: EXPERIMENTAL
Intervention: Implantable loop recorder (ILR) with continuous electrocardiographic monitoring
Number of subjects: 6000

Group type: COMPARATOR
Intervention: Control group (no ILR)
Number of subjects: 6000
Study: 25844995

Group type: EXPERIMENTAL
Intervention: Surgical decompression
Number of subjects: 169

Group type: COMPARATOR
Intervention: Physical therapy (PT)
Number of subjects: 169
Study: 23719048

Group type: EXPERIMENTAL
Intervention: active tDCS+CT
Number of subjects: 60

Group type: COMPARATOR
Intervention: sham tDCS+CT
Number of subjects: 60

Group type: COMPARATOR
Intervention: tDCS-only
Number of subjects: 60
Study: 21585059

Group type: EXPERIMENTAL
Intervention: Waiguan (SJ 5) group
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Non-acupoint group
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (NASF)
Number of subjects: 18
Study: 20051095

Group type: EXPERIMENTAL
Intervention: 75 microg EGF
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: 25 microg EGF
Number of subjects: 149

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 149
Study: 16455426

Group type: EXPERIMENTAL
Intervention: Low-dose anthracycline (doxorubicin 50-125 mg/m2)
Number of subjects: 23
Study: 15372177

Group type: EXPERIMENTAL
Intervention: Complete prone position (CPP, 180 degrees)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Incomplete prone position (IPP, 135 degrees)
Number of subjects: 59
Study: 11505129

Group type: EXPERIMENTAL
Intervention: Rapid fat infusion (0.4 x resting energy expenditure over 6 hrs)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Slow fat infusion (0.4 x resting energy expenditure over 24 hrs)
Number of subjects: 18
Study: 9250846

Group type: EXPERIMENTAL
Intervention: Enoxaparin (low-molecular-weight heparin) 1 mg/kg body weight, subcutaneously twice daily for 48 hours to 8 days
Number of subjects: 3171

Group type: COMPARATOR
Intervention: Unfractionated heparin, continuous intravenous administration for 48 hours to 8 days
Number of subjects: 3171

Group type: EXPERIMENTAL
Intervention: Enoxaparin (low-molecular-weight heparin)
Number of subjects: 3171

Group type: COMPARATOR
Intervention: Unfractionated heparin
Number of subjects: 3171
Study: 7685749

Group type: EXPERIMENTAL
Intervention: MOPP chemotherapy followed by high-dose (40 Gy) total or subtotal nodal irradiation
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: MOPP/ABVD chemotherapy followed by high-dose (40 Gy) total or subtotal nodal irradiation
Number of subjects: 70
Study: 3494461

Group type: EXPERIMENTAL
Intervention: Cimetidine (24 mg/kg/day) for 4 days
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 33
Study: 31888928

Group type: EXPERIMENTAL
Intervention: NOAC-based treatment strategy
Number of subjects: 0

Group type: COMPARATOR
Intervention: INR-guided VKA-management
Number of subjects: 0
Study: 28682187

Group type: EXPERIMENTAL
Intervention: Loss-framed message emphasizing consequence of not receiving flu vaccine
Number of subjects: 163

Group type: COMPARATOR
Intervention: Loss-framed message emphasizing consequence of receiving flu vaccine
Number of subjects: 163
Study: 26138866

Group type: EXPERIMENTAL
Intervention: 100 mg retosiban
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: 800 mg retosiban
Number of subjects: 52

Group type: COMPARATOR
Intervention: 400 mg moxifloxacin (positive control)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Supratherapeutic exposure of retosiban
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Therapeutic exposure of retosiban
Number of subjects: 52
Study: 23828160

Group type: EXPERIMENTAL
Intervention: Olanzapine/Reboxetine (4 mg BID)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Olanzapine/Placebo
Number of subjects: 54
Study: 21976525

Group type: EXPERIMENTAL
Intervention: Consistent group (always reinforced with a specific reward outcome)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Inconsistent group (reinforced with randomly selected rewards)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ACC activity
Number of subjects: 0
Study: 18304693

Group type: EXPERIMENTAL
Intervention: Nesiritide plus protocol-specified standard therapy
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo plus standard therapy
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Nesiritide
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Nesiritide and Placebo
Number of subjects: 101
Study: 16565626

Group type: EXPERIMENTAL
Intervention: Chan‐Chuang qi‐gong therapy for 21 days
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 67
Study: 15194373

Group type: EXPERIMENTAL
Intervention: Daclizumab induction with systemic-enteric drainage (S-E)
Number of subjects: 297

Group type: EXPERIMENTAL
Intervention: Daclizumab induction with portal-enteric drainage (P-E)
Number of subjects: 297

Group type: EXPERIMENTAL
Intervention: Daclizumab induction with systemic-bladder drainage (S-B)
Number of subjects: 297

Group type: COMPARATOR
Intervention: No-antibody induction
Number of subjects: 297
Study: 10856733

Group type: EXPERIMENTAL
Intervention: L-carnitine (2 g/day) added to therapy in group I (n=31)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group (group II, n=20) without L-carnitine
Number of subjects: 51
Study: 9062490

Group type: EXPERIMENTAL
Intervention: Acipimox (oral administration during the last 8 hours)
Number of subjects: 9
Study: 8342836

Group type: EXPERIMENTAL
Intervention: Esophageal Detector Device (EDD)
Number of subjects: 500

Group type: COMPARATOR
Intervention: Capnography
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Overall results from EDD
Number of subjects: 500
Study: 3518499

Group type: EXPERIMENTAL
Intervention: Women told they would be tested for marijuana, alcohol, and other drugs
Number of subjects: 2

Group type: COMPARATOR
Intervention: Women not told they would be tested
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Urine assays
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Tested women
Number of subjects: 2
Study: 29657206

Group type: EXPERIMENTAL
Intervention: Low-dose intradermal (ID) route: 10 μg of vaccine weekly for 8 weeks (total 40 μg)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: High-dose intradermal (ID) route: 40 μg of vaccine at 1-month intervals (total 80 μg)
Number of subjects: 56
Study: 26978277

Group type: EXPERIMENTAL
Intervention: Injunctive norms feedback regarding intoxicated behaviors
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Injunctive norms feedback regarding safe drinking strategies
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Injunctive norms feedback regarding drinking-related consequences
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Injunctive norms feedback regarding drinking behaviors of potential partners
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: General injunctive norms
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Pro-moderation statements
Number of subjects: 221
Study: 24279907

Group type: EXPERIMENTAL
Intervention: Nasya/Prevalin
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (saline spray)
Number of subjects: 20
Study: 22821660

Group type: EXPERIMENTAL
Intervention: Fuzheng Huayu Tablet (FZHYT)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Conventional therapy combined with placebo (Control)
Number of subjects: 180
Study: 20547620

Group type: EXPERIMENTAL
Intervention: Tubular discectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional microdiscectomy
Number of subjects: 0
Study: 18656052

Group type: EXPERIMENTAL
Intervention: 4% CHG soap (group 1A)
Number of subjects: 60

Group type: COMPARATOR
Intervention: 2% CHG-impregnated polyester cloth (group 1B)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 4% CHG soap (group 2A)
Number of subjects: 60

Group type: COMPARATOR
Intervention: 2% CHG-impregnated polyester cloth (group 2B)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 4% CHG soap (group 3A)
Number of subjects: 60

Group type: COMPARATOR
Intervention: 2% CHG-impregnated polyester cloth (group 3B)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 4% CHG soap (group 1A, 2A, 3A)
Number of subjects: 60

Group type: COMPARATOR
Intervention: 2% CHG-impregnated polyester cloth (group 1B, 2B, 3B)
Number of subjects: 60
Study: 15754890

Group type: EXPERIMENTAL
Intervention: Cast post‐and‐core restorations
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Direct post and composite core restorations
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Post‐free all‐composite cores
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Remaining dentin height (substantial)
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Remaining dentin height (minimal)
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Overall survival rate of all restorations
Number of subjects: 249
Study: 12357165

Group type: EXPERIMENTAL
Intervention: 0.2% ropivacaine infusion
Number of subjects: 30

Group type: COMPARATOR
Intervention: 0.9% saline infusion
Number of subjects: 30
Study: 11408334

Group type: EXPERIMENTAL
Intervention: Interferon beta-1b (IFNbeta-1b)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study: 9236561

Group type: EXPERIMENTAL
Intervention: Nefopam hydrochloride, 0.3 mg/kg
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Meperidine hydrochloride, 0.7 mg/kg
Number of subjects: 45

Group type: COMPARATOR
Intervention: Saline solution (Control)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Nefopam hydrochloride (for control group patients with persistent shivering)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Meperidine hydrochloride (for control group patients with persistent shivering)
Number of subjects: 45
Study: 8435601

Group type: EXPERIMENTAL
Intervention: Family Smoking Education project (FSE)
Number of subjects: 4538

Group type: EXPERIMENTAL
Intervention: Smoking and Me project (SAM)
Number of subjects: 4538

Group type: EXPERIMENTAL
Intervention: Both projects in sequence (FSE/SAM)
Number of subjects: 4538

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 4538

Group type: EXPERIMENTAL
Intervention: All groups (FSE, SAM, FSE/SAM, Control)
Number of subjects: 4538
Study: 3308584

Group type: EXPERIMENTAL
Intervention: Exogenous insulin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tolazamide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nondiabetic subjects
Number of subjects: 0
Study: 29936408

Group type: EXPERIMENTAL
Intervention: Transcendental Meditation (TM) program
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Transcendental Meditation (TM) program (EEG subgroup)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 96
Study: 26546612

Group type: EXPERIMENTAL
Intervention: Sitagliptin (n=94)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Placebo (n=47)
Number of subjects: 141
Study: 25524655

Group type: EXPERIMENTAL
Intervention: Lower intensity exercise program
Number of subjects: 160

Group type: COMPARATOR
Intervention: Higher intensity exercise program
Number of subjects: 160
Study: 22948735

Group type: EXPERIMENTAL
Intervention: Magnified visual feedback (1° and 4°) during position-holding contractions
Number of subjects: 22

Group type: COMPARATOR
Intervention: No visual feedback (removed from 15 to 25 seconds during trials)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Visual feedback at 0.1°
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Visual feedback at 1°
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Visual feedback at 4°
Number of subjects: 22
Study: 20923005

Group type: EXPERIMENTAL
Intervention: 1,8‐cineol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Jasmine absolute ether
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Peppermint essential oil
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Linalyl acetate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0